What Are Probiotics?

The WHO and FAO define probiotics as 'live microorganisms that, when administered in adequate amounts, confer a health benefit on the host'. This definition has three non-negotiable elements. First, live microorganisms: dead bacteria are not probiotics, they are postbiotics - a distinct category with different mechanisms and applications. Second, adequate amounts: there is a dose threshold below which probiotic strains produce no measurable benefit. Most clinical trials use 10^8 to 10^11 CFU (colony forming units) per day; products providing less than 10^8 CFU may be ineffective regardless of strain quality. Third, documented health benefit: the benefit must have been demonstrated for the specific strain (not just the species) at the specific dose for the specific application. This last point is where most consumer probiotics fail.

Probiotic research is strain-specific. Lactobacillus rhamnosus GG and Lactobacillus rhamnosus Lcr35 are the same species but have profoundly different properties: LGG adheres well to gut mucus and has strong evidence for diarrhoea prevention; Lcr35 has evidence for vaginal health. Bifidobacterium longum 35624 has specific immunological effects in IBS; Bifidobacterium longum NCC3001 has evidence for depression in IBS patients; Bifidobacterium longum 1714 has evidence for stress reduction in healthy adults. None of these can be extrapolated to generic 'Bifidobacterium longum' - the strain number is what matters. When evaluating a probiotic product, find the alphanumeric strain designation (GG, 35624, BB-12, 1714, 299v) and verify it matches strains used in clinical trials for your intended application.

Probiotics exert effects through four main mechanisms. Competitive exclusion: they colonise mucosal surfaces, competing with pathogenic and dysbiotic bacteria for binding sites and nutrients. Gut barrier reinforcement: certain strains upregulate tight junction proteins (occludin, claudin, ZO-1), sealing the epithelial barrier against toxin translocation. Immune modulation: probiotics stimulate secretory IgA at mucosal surfaces and modulate systemic cytokine profiles, either promoting anti-inflammatory Treg responses or stimulating innate immunity depending on the strain. Short-chain fatty acid production: probiotic bacteria ferment dietary fibre to produce butyrate, propionate, and acetate - colonocyte fuel, barrier-fortifying agents, and satiety signalling molecules. Different strains contribute to different mechanisms; multi-strain formulas with distinct mechanisms can provide broader coverage.

Six markers distinguish quality probiotics from ineffective products. One: named strains with alphanumeric designation (not just species names). Two: CFU guarantee at time of expiry, not manufacture. Three: dose that matches clinical trial evidence for the intended application. Four: appropriate storage and packaging (most Lactobacillus and Bifidobacterium strains require cool, dry storage; some require refrigeration). Five: enteric-coated or acid-resistant capsule to survive gastric transit, or demonstrated acid tolerance in the strain's clinical trials. Six: prebiotic inclusion (synbiotic) or recommendation to take with food to support colonisation efficiency. LOOM Gut Health is formulated against all six of these criteria.